Document is current

Article History

Received: 31 March 2025

Accepted: 10 March 2026

First Online: 30 April 2026

Declarations

:

: Anju T. Peters has received research support from AstraZeneca, Insmed, Regeneron Pharmaceuticals Inc., and Sanofi; and has been a consultant for Chiesi, Eli Lilly, and GSK. Andréanne Côté is or has been an advisory board member for AstraZeneca, GSK, Sanofi, and Valeo; has received speaker fees from AstraZeneca, Covis, GSK, and Sanofi; and has undertaken research for AstraZeneca and GSK. Xavier Muñoz is or has been a speaker and scientific advisor for and received clinical trial investigator fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Faes Farma, GSK, Menarini, Mundipharma, Novartis, Sanofi, and Teva. Changming Xia, Scott Nash, and Yamo Deniz are employees and shareholders of Regeneron Pharmaceuticals Inc. Harry J. Sacks is an employee of Regeneron Pharmaceuticals Inc. and may hold stock and/or stock options in the company; he was also a former shareholder of Optinose Inc. Megan Hardin, Lucía de Prado Gómez, and Paul J. Rowe are employees of Sanofi and may hold stock and/or stock options in the company. Juby A. Jacob-Nara was a former employee of Sanofi (at the time of the study) and may hold stock and/or stock options in the company.

: RAPID is being conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements. The RAPID protocol was reviewed and approved by institutional review boards or ethics committees before patient recruitment. All patients provided written informed consent. For patients under the age of 18 years, both parental/legal guardian consent and patient assent were required.